Ignite Creation Date:
2024-05-06 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 1:53 PM
Study NCT ID:
NCT04700124
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-01-26
First Post:
2021-01-05
Brief Title:
Perioperative Enfortumab Vedotin EV Plus Pembrolizumab MK-3475 Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer MIBC MK-3475-B15 KEYNOTE-B15 EV-304
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-04-21
Start Date Type:
ACTUAL
Primary Completion Date:
2026-12-23
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12-23
Completion Date Type:
ESTIMATED
First Submit Date:
2021-01-05
First Submit QC Date:
January 5 2021
Study First Post Date:
2021-01-07
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-01-25
Last Update Post Date:
2024-01-26
Last Update Post Date Type:
ACTUAL